No Data
No Data
Iseki & Co Sees FY Net Y3.00B
Iseki & Co 1Q Net Y1.49B Vs Net Y1.52B
List of stocks breaking out of the cloud (Part 1) [Ichimoku Kinko Hyo Cloud Breakout Stock List]
○ List of Stocks That Have Broken Through the Cloud Market Code Stock Name Closing Price Leading Span A Leading Span B Tokyo Stock Exchange Prime Market Life Drink C 1,511 1,289 1,419.5 Gloving 2,522 2,333.5 2,367.5 Ai HD 2,803 2,797 2,790.5 Vital KSK 1,477 1,456 1,440.5 StarTia H 2,957 2,75
ISEKI Agricultural Machinery reported double-digit revenue growth and a significant increase in operating and recurring profits in Q1, with steady performance in both domestic and overseas sales.
Iseki & Co., Ltd. <6310> announced its consolidated financial results for the first quarter of the fiscal year ending December 2026 (January-March 2026) on the 15th. Revenue increased by 11.5% year-on-year to 51.471 billion yen, operating income surged by 88.5% to 2.603 billion yen, ordinary income rose by 160.4% to 2.552 billion yen, and quarterly net income attributable to parent company shareholders decreased by 1.9% to 1.486 billion yen. Domestic revenue grew by 8.1% year-on-year to 28.612 billion yen. Robust demand for agricultural machinery and work equipment was a contributing factor.
Attention is focused on the market reaction to Kioxia's earnings report.
[Opening Comments on Stock Market] The Japanese stock market on the 18th is likely to open lower, but after the initial selling pressure eases, the market is expected to focus on semiconductor and AI-related stocks. On the 15th, the U.S. market saw the NY Dow drop by 537 points and Nasdaq fall by 410 points. A lack of progress in negotiations toward ending hostilities between the U.S. and Iran weighed on sentiment, with WTI crude oil futures rising to over $105 per barrel. The CME Nikkei 225 futures were down 215 points from Osaka at 61,825 yen. The yen exchange rate was 1 dollar...
Terumo reported an 11.8% increase in operating profit to 176.3 billion yen for the fiscal year ending March 26, and forecasts a 27.3% increase to 224.5 billion yen for the fiscal year ending March 27.
Terumo <4543> announced its consolidated financial results for the fiscal year ending March 2026, reporting a 9.2% year-on-year increase in revenue to 1.131877 trillion yen and an 11.8% rise in operating income to 176.32 billion yen. In the cardiovascular company segment, overseas operations grew across all businesses, particularly driven by the interventional systems business. Additionally, in the Blood and Cell Technologies Company segment, global expansion of the plasma innovation business accelerated in North America, contributing to overall growth.